Coya Therapeutics (NASDAQ:COYA) Earns “Buy” Rating from Chardan Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a report released on Monday, Benzinga reports. They presently have a $14.00 price objective on the stock. Chardan Capital’s target price indicates a potential upside of 62.79% from the company’s current price.

Coya Therapeutics Trading Up 2.0 %

COYA stock opened at $8.60 on Monday. The business’s 50-day moving average is $9.19 and its 200 day moving average is $7.16. Coya Therapeutics has a 12-month low of $3.21 and a 12-month high of $10.69. The stock has a market cap of $125.56 million, a price-to-earnings ratio of -11.03 and a beta of 0.80.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Tuesday, March 19th. The company reported $0.15 EPS for the quarter. The firm had revenue of $6.00 million during the quarter.

Institutional Investors Weigh In On Coya Therapeutics

A number of large investors have recently made changes to their positions in COYA. CM Management LLC boosted its stake in Coya Therapeutics by 66.7% during the third quarter. CM Management LLC now owns 100,000 shares of the company’s stock worth $384,000 after buying an additional 40,000 shares during the last quarter. AIGH Capital Management LLC raised its stake in Coya Therapeutics by 92.6% during the fourth quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock worth $7,381,000 after purchasing an additional 496,183 shares during the period. Finally, Greenlight Capital Inc. boosted its holdings in Coya Therapeutics by 172.2% in the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock valued at $9,441,000 after purchasing an additional 805,959 shares during the last quarter. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.